Gamma Medica Wins Los Angeles Business Journal Innovation Award

Tools

Gamma Medica Wins Los Angeles Business Journal Innovation Award

<0> For Gamma Medica, Inc.Kathleen Rowe, 781-455-9050 </0>

Medical imaging company has been named a winner of the Los Angeles Business Journal’s 2012 Patrick Soon-Shiong Innovation Awards at a November 15 ceremony. The company develops and markets the LumaGEM® Molecular Breast Imaging (MBI) System, which allows physicians to identify tumors in dense breast tissue. The awards were created to honor and acknowledge the people and organizations around Los Angeles that continue to stretch boundaries. Gamma Medica is one of five 2012 winners to be highlighted in a November 26 supplement of the publication.

“Innovation translates invention into commercial success by matching customer needs with the best solution we can imagine,” said James Hugg, Ph.D., CTO at Gamma Medica. It is very difficult to discern lesions using mammography for the approximately 40% of women who have dense breasts, where fibrous tissue blocks the view. California passed legislation this year that requires clinics to notify women if they have dense breast tissue so they can make informed choices about screening. “LumaGEM’s 91% sensitivity and 93% specificity allows physicians to detect cancer earlier and reduce unnecessary mastectomies and other procedures,” said Hugg.

“We are honored to receive this award. It’s a recognition of the dedication of our team to pursue the best possible medical technology for early diagnosis of breast disease,” said Jim Calandra, CEO. “Gamma Medica is the leading technology in molecular breast imaging. Our advanced technology and our focus on customer service help us carry out our mission of ‘Excellence through Innovation.’”

Gamma Medica, Inc. () is dedicated to leading medical imaging into a new digital era with its Clinical and Pre-Clinical divisions. The Clinical Division designs, builds and services the LumaGEM® Molecular Breast Imaging (MBI) System. The LumaGEM® MBI System is the first commercially available, FDA-cleared, planar, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology used for breast imaging.